Syntiron, Saint Paul, MN, USA
https://syntiron.com/

Syntiron is developing an Alloy Vaccine (Alloy-EK) to prevent neonatal sepsis. Alloy-EK targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.

Babies at risk for neonatal sepsis are too young to be immunized, so Alloy-EK would be administered to expectant mothers to protect their infants. Administering the vaccine to pregnant mothers may simultaneously reduce the risk of infections in mothers that are caused by the same bacteria.

Current Development Stage: Lead optimization

CARB-X Investment: US$1.7 million

Initial CARB-X Investment Date: January 18, 2024